Prevalence
No studies were identified whose primary aim was to establish the prevalence of the target conditions. Prevalence estimates ranging from 2.4 to 6.1% (all target condition combined) were sourced from retrospective analyses of hospital records and from observational studies of the yield from screening programmes. On the basis of these figures, it was concluded that the target conditions were suYciently prevalent to justify a consideration for screening.
Natural history
The reviewers were unable to locate any studies designed with the intention of documenting natural history although some background data were gleaned from studies which did not meet the review's strict inclusion criteria. The report notes that without a clear picture of natural history, one cannot appraise treatment eVectiveness in the absence of a no treatment control group.
The report makes several references to the possibility that amblyopia may, under certain circumstances, undergo spontaneous remission. While this phenomenon has been reported in patients who subsequently suVer a loss of vision in their fellow eye 2 it is not generally thought to occur in the natural course of events. In one study, repeatedly cited in the report, 3 in which evidence for spontaneous remission was found, the investigators' alternative explanation is not acknowledged.
Disability
The search for studies on disability proved more productive. Twenty one relevant studies were identified covering five diVerent study designs. None the less, the reviewers were unable to find evidence suYcient to "...oVer any advice to parents if the target conditions are left untreated." No evidence could be found to substantiate claims that either refractive errors or NCOS were disabling.
Treatment
Evidence to support the eVectiveness of orthoptic treatment (including occlusion therapy) was deemed "disappointing" but did however "substantiate clinical beliefs that children with amblyopia do improve during treatment." However, in referring back to the lack of evidence of the natural history of the target conditions, the reviewers stress that the evidence "...falls very far short of showing that treatment works." Subsequent commentators 4 have pointed out that, for the most part, the evidence underpinning amblyopia treatment stems from animal, rather than from human, studies which were not appraised by the report. It is the former body of work by, among others, the Nobel laureates Hubel and Wiesel, which exerted a powerful influence on clinical practice and largely explains why treatment trials, particularly those with a "no treatment arm," have not been undertaken. None the less, it should be borne in mind that much of the animal literature relates to amblyopia arising from stimulus deprivation-a condition whose pathophysiology may diVer substantially from that of the target conditions.
Screening
Studies of orthoptic screening provided "reasonable" evidence that it could be undertaken in the UK with acceptable uptake and referral rates. Only one prospective controlled trial was identified comparing diVering screening protocols (principally in terms of the professions involved). Primary orthoptic screening was found to be superior to that provided by other professional groups in detecting amblyopia and refractive errors (but not necessarily squint) but did not support the conclusion that the prevalence of amblyopia was reduced at 7 years of age.
Comment
The conclusions of the report are acknowledged to diVer from those previously published which have judged PSVS to be worthwhile. [5] [6] [7] This is attributed to a more rigorous approach in reviewing disability and treatment studies undertaken by the present report.
Given its findings, it is perhaps unsurprising that the report's recommendations are forthrightly expressednamely, that new screening programmes should not be implemented and that current programmes should only be continued in the context of a controlled trial of treatment. The forcefulness of this statement is backed up by the assertion that "the ethical basis for such interventions (that is, screening) is very insecure" (my parenthesis).
Is it unethical to screen in the absence of good evidence of its eVectiveness? All but the most evangelistic proponents of evidence based medicine would argue that a lack of evidence of eVectiveness is not evidence of ineVectiveness; in a routine clinical setting this permits the treatment of patients according to prevailing clinical wisdom even where rigorous proof of both treatment eVectiveness and of a significant risk of disablement is lacking. However, others claim that when screening is considered, a "higher burden of proof" is required such that, in contrast with the routine clinic setting, no evidence of eVectiveness is suYcient evidence of ineVectiveness. 8 The argument runs that when undertaking screening one is making the implicit assumption that screening will benefit the child and that this needs to be firmly established before screening can be justified. Screening programmes carry inherent risks 9 ; in the present case, orthoptic treatment and spectacle wear have the potential to adversely influence the child's psychological wellbeing. 10 Further, if amblyopia cannot be shown to be disabling how can it be possible to obtain informed consent for treatment? Critics of this position would claim that evidence for actual harm being caused is far from firmly established and that it is self evident that a reduction in visual acuity and stereopsis must be disabling-certainly there are occupational consequences.
Perhaps in anticipation of protestations, the report's authors have latterly addressed the consequences of scrapping PSVS. 11 Here, they acknowledge the likely detrimental eVect on the orthoptic profession, and on parents and teachers who, for many years, have been advised of the importance of screening. They also point out that once scrapped, PSVS could not be rapidly re-established. As a solution to this dilemma they suggest that parents should be provided with written information addressing the shortcomings of our knowledge as highlighted in the report. It might be argued that were this to accurately reflect the report's conclusions, albeit in lay language, the uptake to any programme might be so small as to render it unviable.
If those who have invested time and eVort in promoting or undertaking PSVS feel that the rug has been pulled from under their feet, those with a research agenda relating to the target conditions should be buoyed up. Recommendations for future research included in the report are wide ranging with key questions being posed under all topics covered by the review. Even here though the report courts controversy; a proposed investigation into the eVectiveness of orthoptic treatment calls specifically for a randomised trial involving a no treatment control group-something that many clinical investigators, not to mention research ethics committees, may balk at.
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